Buy the Pullback in Iovance - Nr. 1 TIL Franchise with Multi-Year Upside
Iovance (IOVA) is a high-risk, high-reward name: approved autologous TIL therapy (Amtagvi/lifileucel) is producing meaningful revenue growth and best-in-class real-world response rates, while the stock is depressed near $3.30 with heavy short interest. We favor buying a measured pullback for multi‑quarter upside, with disciplined risk controls.